Some patients still have leukemia cells in their bone marrow after chronic myeloid leukemia (CML) treatment with the tyrosine kinase inhibitors (TKIs) Gleevec®, Tasigna® or Sprycel®. This is called refractory leukemia or drug resistance. Other patients taking a TKI may find that the drug no longer works for them, called a loss of response. If a patient's disease returns, it is called a relapse.
The following are treatments for patients with refractory and relapsed CML.
- Bosutinib (Bosulif®)
- Omacetaxine mepesuccinate (SynriboTM)
- Ponatinib (Iclusig®)
For information about the drugs mentioned on this page, visit Drug Listings.
If your CML doesn't respond effectively to drug therapy, your doctor will discuss additional options such as a clinical trial or allogeneic stem cell transplantation. Other treatment choices are a second allogeneic transplant or donor lymphocyte infusion.